Since the middle of 2022, when their GLP-1 agonists became recognized as effective treatments for obesity in addition to diabetes, the stock prices of Novo Nordisk A/S and Eli Lilly and Company have soared. Second-quarter earnings reports from both companies firstly led to some weakness for Novo, but then demonstrated that this is not a zero-sum game.
Stock Watch: Some Turbulence As Novo And Lilly Report Results
Investors Should Value Birds In The Hand Above Fledglings In The Bush
Novo disappointed on high expectations with its second-quarter announcement resulting in stock price weakness. But after Lilly reported without disappointment, something unexpected happened.
